The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 66 of the 168 sources its claims cite were checked for support.
A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance
Open accessAbstract
Data show that insulin degludec has a half-life of >25 h and reaches steady state within 3 days of administration. The pharmacokinetic profile demonstrates an even distribution of exposure across one dosing interval.
Overview
CoChat Summary
## TL;DR
This review summarizes pharmacological studies of insulin degludec (IDeg) and argues that its ultra-long, flat profile and lower day-to-day variability may translate into more flexible dosing and less hypoglycaemia. The paper reports a half-life of >25 h, steady state within 3 days, duration of action beyond 42 h, and four-times lower within-subject variability than insulin glargine.
## Key findings
- IDeg forms multi-hexamers after subcutaneous injection, creating a soluble depot from which insulin is slowly and continuously absorbed; in contrast, insulin glargine forms microprecipitates that must re-dissolve before absorption.
- In pharmacokinetic studies, IDeg reached clinical steady state within 3 days, had a half-life of >25 h, and showed evenly distributed exposure across a 24 h dosing interval.
- In pharmacodynamic studies, IDeg had a flat, stable glucose-lowering effect across 24 h and an ultra-long duration of action exceeding 42 h in subjects with type 1 diabetes; in type 2 diabetes, duration of action was beyond 26 h.
- In a randomized double-blind crossover trial in type 1 diabetes, within-subject variability in glucose-lowering effect was four-times lower with IDeg than with insulin glargine (CV 20% vs 82%; p < 0.0001), and the projected risk of more than double the usual maximum effect was <0.1% for IDeg vs 11% for glargine.
## Methods
- Narrative review of pharmacokinetic and pharmacodynamic studies of IDeg, drawing on multiple clinical trials and phase III data; the paper states the BEGIN clinical trial programme included over 11,000 patients in more than 40 countries.
- Across studies, data collection was standardized: blood sampling for pharmacokinetic endpoints and euglycaemic clamp procedures for pharmacodynamic endpoints, with mostly steady-state designs and limited study centers to reduce variability.
- Main analyses included concentration–time profiles, glucose infusion rate outcomes from clamp studies, linear mixed models on log-transformed pharmacodynamic endpoints, and comparisons/meta-analysis versus insulin glargine.
## Limitations
- The paper states that most studies used steady-state conditions, but some special-population studies used single-dose designs and simulated steady-state profiles instead, which may limit direct comparability across all settings.
- The review notes that IDeg had not yet been approved in the USA at the time, and that cardiovascular safety concerns from FDA review were still being addressed in an ongoing outcomes trial (DEVOTE); this indicates the clinical safety picture was still incomplete.
- Evident from the text: this is a review article summarizing published studies rather than a new primary study, so its conclusions depend on the design and populations of the underlying trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Conceptual model demonstrating action profiles with once-daily dosing of a basal insulin with duration of action a ≤24 h and b substantially longer than 24 h [14]](https://figures.cochat.ai/paper-figures/ce556b7a60544b4e9ef689adea2badcc/a-review-of-the-pharmacological-properties-of-insulin-degludec-and-their-figure-1.jpg)
![Fig. 2 Mechanism of protraction of insulin degludec (IDeg) and visualisation of IDeg using electron microscopy. a Schematic representation of the formation of IDeg multi-hexamers in the subcutaneous depot from di-hexamers in the pharmaceutical formulation [adapted from Jonassen et al. [16] (Fig. 5, p. 2,112), with kind permission from Springer Science + Business Media). b A transmission electron microscope image showing the effect of phenol on IDeg multi-hexamer linkage—the figure depicts elongated IDeg structures in the absence of phenol; the scale bar represents 200 nm (adapted and reprinted with permission from Steensgaard et al. [18]; Copyright 2014 American Chemical Society)](https://figures.cochat.ai/paper-figures/b25b4ee8a5934bb3bbbc5177ca1e7c78/a-review-of-the-pharmacological-properties-of-insulin-degludec-and-their-figure-2.jpg)
![Fig. 3 Concentration–time profiles of insulin degludec 100 U/mL (IDeg U100) dosed at 0.4 U/kg in subjects with a type 1 diabetes mellitus [34] or b type 2 diabetes (data taken from Heise et al. [21]). Also shown are the concentration–time profiles for c IDeg U100 and IDeg 200 U/mL (IDeg U200) dosed at 0.4 U/kg in subjects with type 1 diabetes [reproduced from Korsatko et al. [20], Fig. 2a, p. 518], with kind permission from Springer Science + Business Media)](https://figures.cochat.ai/paper-figures/e21ad676a84a4520be9a4ab244f9fbe4/a-review-of-the-pharmacological-properties-of-insulin-degludec-and-their-figure-3.jpg)
![Fig. 4 Glucose infusion rate profiles with insulin degludec (IDeg) for subjects with a type 1 diabetes mellitus [23], b type 2 diabetes (reproduced from Heise et al. [21], with permission from John Wiley and Sons, Inc.) and c different race or ethnic backgrounds with type 2 diabetes (reprinted from Hompesch et al. [25], with permission from Elsevier)](https://figures.cochat.ai/paper-figures/920decabaa7b408986d28a87396c56dd/a-review-of-the-pharmacological-properties-of-insulin-degludec-and-their-figure-4.jpg)
![Fig. 5 Duration of action of insulin degludec (IDeg) as indicated by the duration of blood glucose control during glucose clamp experiments in subjects with a type 1 diabetes mellitus (0.6 U/kg) [15] or b type 2 diabetes (reproduced from Heise et al. [21], with permission from John Wiley and Sons, Inc.)](https://figures.cochat.ai/paper-figures/c1eeaaaf28a14a4eb6e579fa2ab1fe40/a-review-of-the-pharmacological-properties-of-insulin-degludec-and-their-figure-5.jpg)
![Fig. 6 Subject-specific day-to-day variability in the area under the glucose infusion rate curve for insulin degludec (IDeg) or insulin glargine (IGlar) dosed at 0.4 U/kg during one dosing interval (0–24 h) at steady state (reproduced from Heise et al. [22], with permission from John Wiley and Sons, Inc.). CV coefficient of variation](https://figures.cochat.ai/paper-figures/aed9305879344282a5d2ba98f3e0293a/a-review-of-the-pharmacological-properties-of-insulin-degludec-and-their-figure-6.jpg)
![Fig. 7 Day-to-day variability in glucose-lowering effect of insulin degludec (IDeg) and insulin glargine (IGlar) dosed at 0.4 U/kg over 24 h at steady state (reproduced from Heise et al. [22], with permission from John Wiley and Sons, Inc.). AUC GIR area under the glucose infusion rate profile, CV coefficient of variation](https://figures.cochat.ai/paper-figures/ac37fe07755349b6ac72adfa084c3677/a-review-of-the-pharmacological-properties-of-insulin-degludec-and-their-figure-7.jpg)
![Fig. 8 Simulated insulin degludec (IDeg) concentration–time profiles at steady state in smaller children (1–5 years), children (6–11 years), adolescents (12–17 years) and adults (18–65 years) over a 24-h dosing interval. The simulation was made using the final model from a joint analysis of the pharmacokinetic data from a single-dose trial with IDeg in children, adolescents and adults with type 1 diabetes mellitus (N = 36) [29] and steady-state population pharmacokinetic data obtained over 26 weeks in a clinical trial with IDeg in children and adolescents with type 1 diabetes (N = 169) [40]. The profiles shown are (median) for a typical subject in each age group [with body weight (BW) equal to the median BW in that age group]](https://figures.cochat.ai/paper-figures/3594fdb32c974c10b3232cfd86359a01/a-review-of-the-pharmacological-properties-of-insulin-degludec-and-their-figure-8.jpg)
Verification
Claims the paper makes
47 Valid · 2 Not valid · 58 Not checked · 26 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Upon diffusion of phenol following injection, the IDeg di-hexamers open at both ends and lead to the formation of multi-hexamers [16].”
§ A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance > Mechanism of Protraction of Insulin Degludec (IDeg)
What the sources say
- Partly supportedcites [16] Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104–14. sourceExperimental — accuracy not yet measured
The Discussion says that, after injection, phenol diffuses away and insulin degludec dihexamers reorganise into multihexamer chains. It also proposes that the T6 hexamer opens at both poles, allowing chains to form, but explicitly calls this detailed mechanism a plausible hypothesis rather than an established fact. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The protein sequence of IDeg was based on human insulin, modified by acylating DesB30 at the ε-amino group of LysB29 with hexadecandioic acid via a γ-l-glutamic acid linker [16].”
§ A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance > Mechanism of Protraction of Insulin Degludec (IDeg)
What the sources say
- Supportedcites [16] Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104–14. source
The Introduction (Fig. 1 caption) states that insulin degludec is desB30 human insulin acylated at the ε-amino group of LysB29 with hexadecandioic acid via a γ-L-glutamic acid linker. This matches the attributed structural description. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the pharmaceutical formulation, i.e. in the presence of phenol and zinc, the IDeg hexamers adopt a conformation where only one of the ends is available to interact with the side chain of another IDeg hexamer and thus forms stable di-hexamers.”
§ A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance > Mechanism of Protraction of Insulin Degludec (IDeg)
What the sources say
- Partly supportedcites [16] Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104–14. sourceExperimental — accuracy not yet measured
The Discussion says insulin degludec forms stable T3R3 dihexamers in pharmaceutical formulation and that a T3R3 hexamer is open at only one pole. It presents the proposed side-chain interaction between hexamers as a plausible, speculative mechanism, whereas the citing sentence states that interaction as fact. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“With the gradual diffusion of zinc from the ends of the multi-hexamers, terminal IDeg monomers slowly and steadily dissociate, resulting in a slow and gradual delivery of IDeg from the SC injection site into the circulation [16].”
§ A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance > Mechanism of Protraction of Insulin Degludec (IDeg)
What the sources say
- Partly supportedcites [16] Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104–14. sourceExperimental — accuracy not yet measured
The Discussion and Fig. 5 describe zinc diffusion leading to breakdown of multihexamer chains and release of absorbable monomers from their terminal ends. But the paper calls this a proposed mechanism and says further studies are needed to establish its kinetics in vivo; the citing sentence presents it as established. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The pharmacodynamic properties of IDeg are preserved in subjects with T2DM with different race/ethnic backgrounds, as shown in Fig. 4c [25].”
§ A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance > Pharmacodynamic Characteristics of IDeg > Pharmacodynamic Profiles
What the sources say
- Supportedcites [25] Hompesch M, Morrow L, Watkins E, et al. Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, White, and Hispanic/Latino patients with type 2 diabetes mellitus. Clin Ther. 2014;36:507–15. source
The Discussion states that IDeg’s glucose-lowering effect was flat and stable across the 24-hour dosing interval irrespective of race/ethnicity, and that its pharmacodynamic properties were preserved across the groups studied. The Conclusion likewise reports similar responses in African American, Hispanic/Latino, and white patients with T2DM. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
76 more claims · 26 with their cited sources checked
Create a free account to see all 133 claims and to verify the 21 references still open.
- It may state two separate claims as one. 38
- Probably not a substantial claim. 17
Citations
Cites
Summary of product characteristics
(2013) · Pharmaceutical Medicine · doi:10.1093/med/9780199609147.003.0027 · Cited by 1,905
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 2×
“Similar to all insulin analogues, the risk of hypoglycaemia is a major safety concern, and is considered a key obstacle in regulating blood glucose levels by both patients and physicians [10, 57].”
BackgroundHeise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614 · cited 1×
“of hypoglycaemia [11, 12].”
Self-citationPsychological Insulin Resistance in Patients With Type 2 Diabetes
Polonsky, W. H., Fisher, L., Guzman, S., Villa-Caballero, L., & Edelman, S. V. (2005) · Diabetes Care · doi:10.2337/diacare.28.10.2543 · Cited by 551 · cited 1×
“However, this can be perceived as restrictive to patient lifestyle and can create a barrier towards the use of basal insulin therapy [9, 10].”
BackgroundDesign of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448 · cited 6×
“Insulin degludec (IDeg) is a new-generation basal insulin with an ultra-long duration of action developed for once-daily administration [15, 16], which has been designed to address the unmet needs in terms of basal insulin therapy outlined above.”
BackgroundMethodResultInfluentialHeller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 9×
“formed by means of a Biostator (MTB Medizintechnik, Amstetten, Germany) [21, 22] or using a manual clamp, as described previously [20].”
BackgroundMethodInfluentialSelf-citationClinical pharmacokinetics and phamacodynamics: concepts and applications
Rowland, M., & Tozer, T. N. (2011) · Cited by 367
Ratner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346 · cited 3×
“This rationale is furthered supported by the reduction in rates of hypoglycaemia, in particular nocturnal hypoglycaemia episodes, being more prominent with IDeg than with IGlar during the maintenance phase—described as the period (from 16 weeks to end of treatment) when stable glycaemic control and insulin dose have b…”
BackgroundInfluential
Research works printed but not linked: 5
- Dhatariya K, Yeong J. Improved glycaemic controls for patients on twice daily dosing regime of insulin glargine compared to those on a once daily dosing regime. Diabetologia. 2010;53(suppl 1):S390.
- Kurtzhals P, Heise T, Strauss HM, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54(suppl 1):S426.
- Haahr H, Ikushima I, Hirao K, et al. Similar pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese and Caucasian subjects with T1DM [abstract no. PCS-16-6]. J Diabetes Investig. 2012;3(suppl s1):197.
- Leiter L, Yale JF, Chaisson JL, et al. Assessment of the impact of fear of hypoglycemic episodes on hypoglycemia management and glucose control management. Can J Diabetes. 2005;29:186–92.
- Oyer DS, Heller S, Gough SCL, et al. Exercise-related hypoglycaemia occurs at similar frequency with insulin degludec and insulin glargine [abstract]. Diabetologia. 2013;56(suppl 1):S84.
Cited by
Glycaemic variability in diabetes: clinical and therapeutic implications
Ceriello, A., Monnier, L., & Owens, D. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30136-0 · Cited by 588
Insulin analogues in type 1 diabetes mellitus: Getting better all the time
Mathieu, C., Gillard, P., & Benhalima, K. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.39 · Cited by 248
Wysham, C., Bhargava, A., Chaykin, L., de la Rosa, R., Handelsman, Y., Troelsen, L. N., Kvist, K., & Norwood, P. (2017) · JAMA · doi:10.1001/jama.2017.7117 · Cited by 221
Billings, L. K., Doshi, A., Gouet, D., Oviedo, A., Rodbard, H. W., Tentolouris, N., Grøn, R., Halladin, N., & Jodar, E. (2018) · Diabetes Care · doi:10.2337/dc17-1114 · Cited by 193
“The comparison of different basal insulins may be seen as a limitation as they have different pharmacokinetic properties (25).”
BackgroundPharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Polyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. A., Katsiki, N., Underwood, P., Park, K.-H., Seufert, J., Kang, E. S., et al. (2018) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 187
Metadata
- Authors
- Haahr, H., & Heise, T.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Profil Institute for Metabolic Research (DE)
- Corresponding author
- Haahr, Hanne
- Venue
- Clinical Pharmacokinetics
- Published
- 2014-09
- Volume
- 53
- Issue
- 9
- Pages
- 787-800
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC4156782
- OpenAlex
- W2034327086
- Cited by
- 226
- References
- 57
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 15 · 2023: 14 · 2022: 20 · 2021: 21 · 2020: 23 · 2019: 27 · 2018: 24 · 2017: 26 · 2016: 20 · 2015: 17 · 2014: 1
- FWCI
- 3.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- insulin degludec, basal insulin, pharmacokinetics, pharmacodynamics, insulin glargine, glucose-lowering effect, euglycaemic clamp, type 1 diabetes, type 2 diabetes, liver dysfunction, renal dysfunction, elderly patients, ethnic differences
- MeSH terms
- Chemistry, Pharmaceutical, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance. https://app.cochat.ai/papers/10.1007/s40262-014-0165-y
- The paper
- Haahr, H., & Heise, T. (2014). A Review of the Pharmacological Properties of Insulin Degludec and Their Clinical Relevance. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-014-0165-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.